Compare QXO Inc. Common Stock (QXO) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QXO Inc. Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? QXO Inc. Common Stock trades at $10.37 (market cap $11.43B), while Relay Therapeutics Inc. Common Stock trades at $17.07 (market cap $3.81B). The key difference: QXO Inc. Common Stock is far larger — about 3× Relay Therapeutics Inc. Common Stock's market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, QXO Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold QXO Inc. Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.
| QXO | RLAY | |
|---|---|---|
Market Cap | $11.43B | $3.81B |
Volume | 21,645,941 | 1,706,150 |
Sector | Industrials | Health |
52-Week High | $27.07 | $20.75 |
52-Week Low | $10.33 | $6.05 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $16.75B | $2.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.
The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About QXO Inc. Common Stock
QXO, Inc. is a distributor of roofing, insulation, waterproofing, and other building materials, serving contractors and builders across US and Canada through its network of branch locations.
Read more on QXO →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
